Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.

摘要: The anti-CD20, B-cell-specific mAb rituximab (RTX) has been approved for treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis. Under conditions high burden, exhaustion the body's effector mechanisms, example, NK-cell-mediated killing, may lead to substantial decreases in immunotherapeutic efficacy this mAb. Moreover, RTX patients with chronic lymphocytic leukemia levels circulating cells can removal CD20 from cells, thus allowing them persist resist clearance. therapy several autoimmune diseases proven be effective, but numerous instances there little correlation between reductions disease activity changes titers pathogenic autoantibodies. This paradox explained by a separate mechanism: Binding generates immune complexes that act as decoys attract monoycte/macrophages reduce their inflammatory certain autoantibody-mediated diseases. Several second-generation anti-CD20 mAbs enhanced cytotoxic action have developed are being tested clinic cancer application these mAbs, potentially combination modifying drugs, successfully address shortcomings current immunotherapy.